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Aim and background: The aim of this study is to analyze the main clinical and pathologic char-
acteristics of radiation-induced breast carcinomas (BC) following treatment for Hodgkin’s
disease (HD) and to identify the risk factors for their induction. To create a mathematical
model for the prediction of expected age at which a BC might develop based on the age at
treatment for HD.
Materials and methods: Thirty-nine cases of women with BC that developed after treatment
for  HD in puberty or adolescence were analyzed retrospectively. The median age at initia-
tion of treatment for HD was 12.9 years (9–21). The median age at diagnosis of the second
malignancy – breast carcinoma was 32.4 years (22.9–39).
Results: The distribution of patients according to the clinical T stage of breast cancer was
as  follows: 11 patients with T1 stage BC (28%), 22 with T2 stage (56%) and 6 with stage T3
(16%). Prevalent were tumors localized in the lateral breast quadrants. The observed 5 year
survival was 95%.
Conclusion: The risk of solid tumors, especially breast cancer, is high among women with HD
disease who were treated with radiotherapy in their childhood. In this article, we  propose
a  speciﬁc mathematical age formula which could be used as predictive equation when the
age  of the treatment for HD is in the range between 9 and 21 years. Systematic screening fore patbreast cancer in thesimprove their survival.
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Table 1 – Tumor localization, tumor stage and tumor
histology.
Localization of the
tumor in the breast
No. of patients (%)
Lower – medial quadrant 7 (18%)
Lower – lateral quadrant 10 (26%)
Upper – lateral quadrant 7 (18%)
Centrally located 12 (31%)
Upper – medial quadrant 3 (7%)
T stage
pT1a 0 (0%)
pT1B 2 (5%)
pT1c 9 (23%)
pT2 22 (56%)
pT3 6 (16%)
Histological type
ductal in situ 5 (14%)
lobular in situ 0 (0%)
invasive ductal 17 (44%)
Invasive lobular 16 (41%)
Papillary 1 (3%)
T – tumor stage.
Table 2 – N stage, G, LVI, hormonal status, HER 2 status.
N stage No. of patients (%)
pN0 12 (32%)
pN1a 13 (33%)
pN2a 7 (18%)
pN2b 4 (10%)
pN3b 3 (7%)
G
G1 6 (15%)
G2 13 (33%)
G3 20 (51%)
LVI
LVI (−) 22 (56%)
LVI (+) 17 (2%)
Hormonal status
ER, PR (+) 22 (56%)
ER, PR (−) 17 (44%)
HER 2 status
HER 2 (3+) 14 (36%)
HER 2 (−) 25 (64%)
N – lymph nodes, G – degree of malignancy, LVI – lymph-vascular318  reports of practical oncology an
1.  Background  and  Aim
One of the major medical successes in modern day proto-
cols for treatment of hematologic diseases are the results
achieved in the complex therapy of Hodgkin’s disease (HD).1
With the continued overall survival of these patients, an
increase in the frequency of radiation-induced tumors is
observed. A series of investigations have demonstrated an
elevated risk for second malignancies in patients treated
for Hodgkin’s disease.2–4 Acute nonlymphocytic leukemias,
non-Hodgkin’s lymphomas, breast and gastrointestinal car-
cinomas have been described.5–7 Breast cancer is the most
common solid tumor that develops in women following com-
bined curative treatment with chemo- and radiotherapy for
HD.
Previously published data indicate that radiation-induced
breast cancer presents a serious medical problem. In the study
of Bhatia et al. on the late effects of treatment of HD, 88
secondary neoplasms were detected in 1380 patients with
HD. Breast cancer was the most common solid tumor (stan-
dardized incidence ratio 75.3; 95 percent conﬁdence interval,
44.9–118.4), with an estimated actuarial incidence in women
that approached 35 percent (95 percent conﬁdence interval,
17.4–52.6 percent) by 40 years of age.8 To solve this problem,
scientiﬁc research in recent years has focused on the following
areas:
• Identiﬁcation of risk factors for the development of
radiation-induced breast cancer;
• Investigation of their clinical and pathological characteris-
tics;
• Proposals for methods for the monitoring of patients treated
for HD and the introduction of new therapeutic approaches;
2.  Materials  and  methods
We  present the results of our own clinical material consist-
ing of 39 cases followed up retrospectively. Patients have been
treated for HD during childhood and puberty and have devel-
oped breast cancer after a period of 11–23, median period – 17
years.
Tumor localization, tumor stage and the histology of the
tumors are represented in Table 1, while Table 2 shows the
distribution of patients according to their N stage, grade of
malignancy (G), the presence of lympho-vascular invasion
(LVI), hormonal and HER 2 receptor status.
Frequency distributions; 2-square test were used for the
statistical processing of the data; Kaplan–Meier – for survival
analysis, graphical methods, etc.
Upon examination of the linear correlation between the
age at treatment for HD and the age at diagnosis of breast
cancer a coefﬁcient of linear correlation between the two
variables – r = 0.614 was established. Correlation degree of
dependence was classiﬁed as follows: (1) extremely high –
r ≥ 0.9; (2) great 0.9 ≤ r ≤ −0.7; (3) substantial r ≤ −0.5 ≤ 0.7; (4)
moderate r ≤ −0.3 ≤ 0.5; (5) weak – r ≤ 0.3.invasion, hormonal ER, PR – estrogen and progesterone receptor
status, HER 2 status.
3.  Results
The distribution of the patients according to the clinical T
stage of breast cancer was as follows: 11 patients with T1
stage BC (28%), 22 with T2 (56%) and 6 patients with T3 (16%).
Prevalent were the tumors located in the lateral quadrants
17 (44%), followed by the centrally located tumors 12 (31%)
and those in the medial quadrants 10 (25%). In 17 patients
(44%) the histological type was invasive ductal carcinoma, fol-
lowed by invasive lobular carcinoma, observed in 16 patients
(41%) and other rare subtypes (in situ, ductal, lobular) in
6 patients (17%). Twenty-four patients (61%) had metastatic
spread in the regional lymph nodes and in 3 (7%) the paraster-
nal lymph nodes were engaged. In 20 patients (51%) the degree
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Comparing the survival in 298 patients who  have devel-Fig. 1 – Scatter diagram.
f malignancy of the tumor was G3. Twenty-two women (56%)
resented with positive receptor status, and 14 (36%) were
ER2 (3+).
The median age at which the patients were diagnosed with
he second malignancy – breast carcinoma was 32.4 years
22.9–39). The median time from treatment for HD to the
iagnosis of BC was 17.7 years (11.7–24.3). The breast cancer
atients were followed for a median period of 7.6 years (1–10).
he survival which was observed was 95% for 5 year and 38%
or 10 years.
The zero hypothesis was checked with a Chi-square test.
ccording to this hypothesis in the population, from which the
xtract was made, there are no statistically signiﬁcant differ-
nces in the tumor localization rates in the different quadrants
f the beast. The Chi-square test demonstrated that the dif-
erences between the observed and expected rates were not
tatistically signiﬁcant (p = 0.207).
In our analysis a signiﬁcant correlation was found between
he age at diagnosis of BC in years and the natural logarithm
f the age at treatment for HD in years.
This relationship is illustrated by the scatter diagram
hown in Fig. 1. The ﬁnding of signiﬁcant linear correlation
as the basis for the use of a linear regression analysis in
hich the following linear correlation was established:
Age at diagnosis of BC (years) = 3.481 + 11.429 × ln(age at
treatment for HD) (years)
Based on this equation retrospective estimates of the age
ere made to assess how accurate such a prediction may be.
inety-ﬁve percent conﬁdent intervals of the prognosis were
ound.
The results allowed for the use of the predictive equation
hen the age at treatment for HD (years) was in the range
etween 9 and 21 years.
.  Discussionn recent years the risk factors associated with the develop-
ent of radiation-induced breast cancer have been intensivelytherapy 1 9 ( 2 0 1 4 ) 317–321 319
studied. Convincing evidence has been accumulated for the
signiﬁcant role of age during radiation treatment for HD, the
magnitude of the dose realized and radiation technique used.
Radiation-induced tumors of the breast arise most commonly
in the radiation ﬁeld of the axillary and mediastinal lymph
nodes, or at the border with the screened area on average
10–15 years after radiation therapy and continue to occur in
the longest living patients.9 This period corresponds to the
long, multistep process of carcinogenesis, in which ionizing
radiation is the main triggering factor. Despite reports that
the carcinogenic effect of radiation is manifested between the
ﬁfth and ninth year, most solid tumors arise 10 years after
radiotherapy and the risk of developing breast cancer is the
highest after 15 years or more.10–13 These data indicate the
necessity of continued follow-up of patients with HD for early
detection of second malignancies.
The relationship between the dose of irradiation and the
risk for the occurrence of breast cancer has been investigated
in large groups of patients with HD. A number of studies
have found that external beam radiotherapy with a dose
higher than 20 Gy, compared to a lower dose of 20 Gy, is asso-
ciated with a signiﬁcantly higher risk of developing breast
cancer.11 Techniques of radiation applied in the past, the so-
called “mantle ﬁeld” and especially the mandatory irradiation
of axillary lymph nodes, are associated with an increased
risk of developing radiation-induced breast cancer due to the
lack of full protection of the mammary  parenchyma.14,15 Sev-
eral studies have demonstrated a high incidence of bilateral
breast carcinomas (21%) after radiotherapy of lymph chains
above the diaphragm.16,17 No correlation has been established
between the dose of fractionation and the risk of development
of secondary breast cancer.9,18
The importance of age at the time of irradiation for the
onset of secondary breast cancer has been analyzed in a sig-
niﬁcant number of studies. There is certain evidence that
irradiation at a young age is associated with a high risk of
developing radiation-induced breast cancer in patients with
HD. In the study of Hancock et al.9 1993 it has been found that
the risk was the highest in patients irradiated at ages younger
than 15 years – RR 136 (95% CI = 2.5–5.7). With increasing age,
the risk for developing breast cancer declined, but remained
signiﬁcantly high in women who were irradiated under the
age of 30 – RR 19 (95% CI = 10.3–32). Receiving radiation treat-
ment above the age of 30 does not lead to an increased risk RR
0.7 (95% CI = 0.2–1.8).
Other authors have demonstrated higher risk for the devel-
opment of secondary BC in patients who were treated at the
age of 19, or younger compared to those treated in the age
older than 19 years – RR 56 (95% CI = 23.7–107).19 Follow up of
1380 children with HD aimed at determining the risk of occur-
rence of secondary neoplasms has shown that irradiation in
childhood is associated with the highest risk for development
of radiation-induced breast cancer.8 Similar ﬁndings have
been reported by Clemons et al.,20 establishing that the high-
est risk of developing breast cancer is by irradiation between
puberty and the age of 30.oped breast cancer after HD with 405 223 patients with only
breast cancer, the authors report 5 years OS – 77%, 10 years OS
– 59% and 15 years OS – 48% in the group BC after HD versus
d rad
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5 years OS – 89%, 10 years OS – 72% and 15 years OS – 58% in
the group of BC only p ≤ 0.00001 CI (2.17–3.67).21 The observed
OS of the patients in our study was 95%, but statistically sig-
niﬁcant conclusion was difﬁcult to be made, due to the low
number of followed patients.
The question of the existence of clinical and pathological
features that distinguish radiation-induced cancer from the
spontaneously developed one is not fully understood. There
are two published studies comparing the clinical and histo-
logical characteristics of secondary breast cancer that have
developed in women treated for HD with a control group of
women with spontaneously occurring carcinomas.22–24 The
results of the comparative analysis failed to demonstrate any
differences in the survival of patients from both groups. This
implies that radiation-induced cancers do not differ in clinical
course and biological behavior from the spontaneously occur-
ring cancers. Further studies on the problem are needed to
prove or refute this statement.
The limited number of patients in our study does not
allow for statistically valid conclusions, but these data show
that radiation-induced tumors in young women tend to have
a more  frequent metastatic invasion in the regional lymph
nodes, lateral localization, high degree of malignancy G3,
as well as a predisposition for the development of distant
metastases. This gives grounds to assume that the radiation-
induced breast cancer developing in young adulthood has a
more aggressive course and a worse prognosis.
The presented data suggest that patients treated for HD
have a risk for developing radiation-induced BC, which is age-
dependent. With the introduction of modern techniques for
conducting radiation for HD, using linear accelerators, 3D con-
formal planning and treatment, a reduction in the dose to the
breast parenchyma is expected as well as a decrease of the
stochastic risk for a secondary malignant disease, including
breast cancer. As a result of the introduction of more  aggres-
sive combined regimens of chemotherapy for HD, there has
been a decrease in the overall dose of percutaneous radiothe-
rapy, as well as a reduction in the irradiated volumes. There
are ongoing trials in which after an evidence of full control of
the HD on PET-CT, patients are left on dynamic control and
do not receive radiotherapy. This therapeutic approach would
reduce the risk of occurrence of breast cancer associated with
radiation.
The statistical model has indicated that the equation for
predicting the risk of developing BC following treatment for
HD can be used when the age at treatment for HD is between
9 and 21 years.
5.  Conclusion
Patients treated for HD, especially in their childhood and
puberty need to be included in screening programs earlier
than the accepted age limit of 25 years. In addition to the
clinical examination, a mammography or ultrasound mam-
mography is required.Knowledge of the risk factors, biological features and clini-
cal course of radiation-induced breast cancer will help to build
an optimal regimen for the treatment of HD, which will help
achieve the highest survival with minimal late toxicity.
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